| - Maintaining the cerebral flow, especially in FHF cases |
9 |
| - Preserving the cardiac and pulmonary flow |
9 |
| - Maintaining the renal flow and kidney function |
49 |
| - Maintaining hemodynamic stability during the anhepatic phase |
9, 27, 34, 84
|
| - Providing longer anhepatic phase for better surgical performance |
9 |
| - Reduction of intraoperative blood loss |
9, 34 |
| - Improving the clinical outcome |
9, 34 |
|
|
Claimed disadvantages of using VVB
|
|
| - Pulmonary or air emboli, thrombosis |
9, 15, 27 |
| - No evidence of maintaining normal perfusion of abdominal organs |
27 |
| - No evidence on preserving renal function |
38, 39, 49, 55, 83 |
| - Longer operative and warm ischemia time |
42, 83 |
| - Higher rate of post-reperfusion syndrome |
37, 51, 58 |
| - Hypothermia |
15, 85
|
| - Risk of bleeding due to the hemolysis and fibrinolysis in bypass tubes |
35 |
| - Nerve injury, lymphocele, hematoma, wound infection |
9, 15, 27 |
| - No evidence for improving the clinical outcome |
38, 39, 49, 56, 74, 76, 83 |
| - Higher transplant cost |
12, 35 |
